CTS 2024: Faricimab vs aflibercept in the reduction of exudates in Y/R trials
June 10th 2024Jennifer Lim, MD, FARVO, spoke with us about her presentation Faricimab vs aflibercept in the reduction of exudates in Y/R trials" at Clinical Trials at the Summit meeting in Park City, Utah on June 8, 2024.
Read More
ARVO 2024: Reduction in hard exudates with faricimab vs aflibercept in patients with DME
May 19th 2024At this year's ARVO meeting, Roger Goldberg, MD, presented a paper on hard exudates and their resolution in patients with diabetic macular edema treated with either faricimab or 2 mg aflibercept.
Read More
ARVO 2024: Exploratory analysis of pivotal phase 3 trials, YOSEMITE and RHINE, for vabysmo in DME
May 18th 2024At this year's ARVO meeting, Daniela Ferrara, MD, PhD, FASRS, presented a paper on predicting functional outcomes for different treatment durations of faricimab in diabetic macular edema.
Read More
ARVO 2024: Feasibility and clinical efficacy of an OCT B-scan of interest tool
May 16th 2024At this year's ARVO meeting in Seattle, Washington, the Eye Care Network spoke with Niranchana Manivannan, PhD. She spoke about the poster presentation, "Feasibility and clinical efficacy of an OCT B-scan of interest tool."
Read More
ARVO 2024: Predicting 3-year myopia control efficacy from 1-year data
May 13th 2024At this year's ARVO meeting in Seattle, Washington, the Eye Care Network spoke with Noel Brennan, MScOptom, PhD. The clinical research fellow at Johnson and Johnson shared highlights from his presentation on myopia control and predictive modeling.
Read More
ARVO 2024: Post hoc analysis of phase 3 trial on SB15
May 8th 2024At this year's ARVO meeting, SriniVas R Sadda, MD, presented "Post Hoc Analysis of a Phase 3 Trial on SB15 (Proposed Aflibercept Biosimilar): Assessment on Pre-to-Post Switching Efficacy and Safety in Neovascular Age-related Macular Degeneration."
Read More
ARVO 2024: Post-hoc analysis of GOBI and MOJAVE trials for perfluorohexyloctane
May 7th 2024John Sheppard, MD, MSc, FACs, sat down to discuss post-hoc analysis of 2 FDA registration trials for perfluorohexyloctane, GOBI and MOJAVE, at this year's ARVO meeting held in Seattle, Washington, from May 5 to May 9.
Read More